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ABSTRACT
Background and Objectives: This was a multicenter study to evaluate the usefulness of the tumor necrosis factor-alpha 
(TNF-α) blocker infliximab for treatment of Korean pediatric patients with refractory Kawasaki disease (KD). Subjects 
and Methods: Data from 16 patients throughout Korea who were diagnosed with refractory KD and received infliximab 
were collected retrospectively. Results: Complete response to therapy with cessation of fever occurred in 13 of 16 patients. 
C-reactive protein (CRP) concentrations decreased following infliximab infusion in all 14 patients in whom it was measured 
before and after treatment. There were no infusion reactions or complications associated with infliximab except in 1 case 
with acute hepatitis occurring during treatment followed by calculous cholecystitis 4 months later. Fifteen patients had coro-
nary artery (CA) abnormalities before infliximab therapy. Three had transient mild dilatation and 9 had CA aneurysms, 
with subsequent normalization in 4 patients, persistent mild dilatation in 3, persistent aneurysm in 2, and there were 3 cases 
(2 with CA aneurysm, 1 with mild CA dilatation) without follow-up echocardiography. Conclusion: The results of this 
study suggest that infliximab may be useful in the treatment of refractory KD, and it appears that there is no significant fur-
ther progression of CA lesions developing after infliximab treatment. Multicenter trials with larger numbers of patients and 
long-term follow-up are necessary to assess the clinical efficacy and safety of infliximab in refractory KD.  (Korean Circ J 
2010;40:334-338)   
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Introduction
Coronary artery (CA) lesions, including dilatation and 
aneurysms, develop in 15% to 25% of children with untreat-
ed Kawasaki disease (KD).
1)2) Administration of intravenous 
immunoglobulin (IVIG) is now well accepted as the stand-
ard treatment for KD, and reduces the risk of coronary ar-
tery aneurysm (CAA) to 3% to 5%.
3)4) Approximately 10% 
to 20% of patients with KD fail to become afebrile after the 
first dose of IVIG,
5)6) and the current practice for these pa-
tients is to administer repeated doses of IVIG. However, of 
the patients who still remain febrile after repeated doses of 
IVIG, no large randomized controlled clinical trial has es-
tablished their optimal management.
5) These refractory KD 
patients are at a much higher risk for developing CAA. The 
KD patients refractory to IVIG were reported to improve 
and defervesce after steroid therapy in several series,
7) but 
there are several reports concerning the adverse effects of 
steroid treatment. No controlled clinical trials have estab-Min Seob Song, et al.   335
lished their optimal use in managing refractory patients.
Even less data is published on the use of other therapies, 
which may include 1 or more repeat doses of IVIG, high-dose 
pulse methylprednisolone (MP), cyclophosphamide, metho-
trexate, or plasmapheresis in IVIG-refractory KD.
8)9) Recent-
ly, infliximab (Remicade), a monoclonal antibody that blocks 
the biological activity of tumor necrosis factor-alpha (TNF- 
α), was used in a few refractory KD patients and reported to 
be effective and safe.
8)10)
Subjects and Methods
Refractory KD was defined as the persistence or reappear-
ance of fever (≥38.0℃ or 100.4°F) at least 36 hours after the 
last of more than 2 doses of IVIG therapy and high-dose as-
pirin with or without intravenous MP pulse therapy (30 mg/
kg/dose/day). Complete response was defined as the cessa-
tion of fever within 12 hours of infliximab infusion therapy.
Sixteen cases were retrospectively collected from clinicians 
throughout Korea who had used infliximab, a monoclonal 
antibody against TNF-α, for patients with refractory KD be-
tween July 2004 and November 2008.
Sixteen patients with acute KD (13 males, 3 females, medi-
an age 2.8 years, range 0.2-5.8 years) received infliximab in-
fusion after at least 2 doses of IVIG and daily aspirin (50-100 
mg/kg/day) with or without MP pulse therapy for the fol-
lowing indications: 1) persistent or recrudescent fever (14 
patients) and 2) fever plus persistent arthritis (2 patients) 
(Table 1). 
All 16 patients were Korean. All patients had prolonged 
fever and met either 4 of the 5 standard criteria for KD or 3 of 
the 5 criteria in addition to CAA by echocardiography.
9) 
Demographic characteristics, therapies administered, C-
reactive protein (CRP) concentrations before and after inflix-
imab treatment, infliximab dose, response, and coronary ar-
tery (CA) outcomes were recorded for all patients. Illness day 
1 was defined as the first day of fever. 
The internal diameter of the CA measured by transtho-
racic echocardiography was defined as aneurysm with the 
following parameters: 1) if the internal lumen diameter was 
>3 mm in children <5 years old or >4 mm in children >5 
years old; 2) if the internal diameter of a measured segment 
was >1.5 times that of an adjacent segment; or 3) if the coro-
nary lumen was clearly irregular by the Japanese Ministry of 
Health criteria classification.
10)11) CA dilatation was defined 
as CA size larger than normal for age, but no apparent seg-
mental aneurysm. Aneurysms were identified as saccular or 
fusiform.
Results
Treatment and patient outcomes
All patients received more than 2 doses of IVIG. Three pa-
tients received more than 3 doses of IVIG (2 g/kg/dose/day), 
and 11 patients received more than 2 doses of IVIG and MP 
pulse therapy (30 mg/kg/dose/day). 
All patients failed to become persistently afebrile follow-
ing these treatments. Before infliximab therapy, the patients 
Table 1. Patient characteristics and outcomes
Patient 
number
Age
(year)
Sex
1st IVIG
(day)
Illness day 
at treatment
Response* Other treatment
Oral steroid
(Y/N)
Comment
01 3.5 M 5 11 Complete IVIG×2, MP×4 N
02 1.3 M 5 08 No IVIG×3 N One more IVIG
03 4.6 F 5 16 Complete IVIG×2, MP×2 N
04 1.1 M 3 10 Complete IVIG×3, MP×3 N
05 5.4 M 5 25 Complete IVIG×4, MP×4 N Arthralgia
06 0.3 M 4 29 Complete IVIG×2, MP×3 Y Hepatitis, Cholecystitis
07 2.4 F 5 16 Complete IVIG×2, MP×3 N
08 2.0 M 5 16 Complete IVIG×2, MP×2 Y   
09 0.7 M 4 06 No IVIG×2 Y
10 4.7 M 5 21 Complete IVIG×2, MP×1 N Arthralgia
11 0.2 M 6 16, 40 No IVIG×2, MP×3 Y One more infliximab
12 3.9 M 4 19 Complete IVIG×2, MP×3 Y
13 15.0 M 3 20 Complete IVIG×2, MP×3 N
14 2.4 F 4 21 Complete IVIG×2 N
15 5.8 M 5 21 Complete IVIG×2 N
16 2.8 M 5 10 Complete IVIG×2 N
*Complete response: afebrile within 12 hours of infliximab infusion with complete resolution of clinical signs and symptoms. IVIG: intrave-
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had been either persistently or intermittently febrile for 6 to 
40 days. Each of the 16 patients received a single infusion of 
5-6.6 mg/kg of infliximab, with tapering of oral predniso-
lone in 5 patients. Complete response occurred in 13 of the 
16 patients, including 2 patients who achieved both resolu-
tion of fever and accompanying persistent arthritis. There 
were 3 patients who did not achieve complete response. In 
patient no. 2, his fever subsided after infliximab infusion, but 
he was readmitted to another hospital because of recrudes-
cent fever which responded to a fourth dose of IVIG. In pa-
tient no. 9, the frequency and severity of his fever decreased 
from 3-4 times per day at higher than 38.5℃, to 1 time per 
day at around 38℃ for 3 days after infliximab therapy. His 
fever subsided after 1 additional dose of intravenous MP 
pulse therapy, followed by tapering of oral prednisolone. In 
patient no. 11, his fever subsided after infliximab therapy, but 
it recurred 24 days later, after the cessation of oral predniso-
lone therapy. 
Two patients (no. 5 and no. 10) with fever and arthritis tr-
eated with infliximab, achieved dramatic and permanent 
resolution of their arthritis within 12 hours of the infusion. 
In one, infliximab was administered for persistent mild fever 
and severe arthritis, and his arthritis resolved dramatically. 
Likewise, in the other, high fever and persistent arthralgia 
resolved dramatically after infliximab treatment.
There were no infusion reactions to infliximab. However, 
in patient no. 6, acute hepatitis occurred during infliximab 
treatment; this was followed by calculous cholecystitis 4 mon-
ths later, which was managed by supportive care (Table 1). 
Changes in C-reactive protein concentrations
Pretreatment levels were determined within 24 hours be-
fore infliximab infusion, and posttreatment levels within 72 
hours after infusion. All 16 patients had elevated CRP concen-
trations before infliximab infusion, which decreased follow-
ing infusion in all 14 patients for whom data was obtainable 
(Table 2).
Echocardiographic findings of coronary arterys 
Echocardiographic determinations of the maximum in-
ternal diameters of the right and left CAs performed at any 
time during the disease course are shown in Table 2.
Fifteen patients had CA abnormalities (from mild CA dil-
atation to aneurysm) documented by echocardiography be-
fore infliximab therapy. Thirteen patients were followed up 
for 2 to 28 months (median follow-up: 5 months), and 3 cas-
es were without follow-up. Three had transient mild CA dil-
atation that resolved after infliximab infusion, and 9 had 
CAA with subsequent normalization in 4 patients, persistent 
mild dilatation in 3, and persistent aneurysm in 2 on follow-
up echocardiography. Of 3 cases without follow-up echocar-
diography, 2 had CAA and 1 had mild CA dilatation (Table 2).
Discussion
Although IVIG with aspirin therapy is effective for acute 
KD, numerous series have documented a 10% to 20% failure 
rate with persistence of fever and clinical and laboratory signs 
of inflammation.
5)8)12) While a second infusion of IVIG (2 g/
Table 2. CRP values and echocardiographic findings of coronary artery 
Patient
number
CRP (before/after) 
(mg/dL)
Echo on treatment (RCA/LCA)
(mm/mm)*
Echo on follow up (RCA/LCA)
{mm/mm (month)}
01 20.6/12.7 9.0/5.0 6.0/4.0 (28)
02 05.9/NA WNL/3.100. WNL/WNL (2)
03 08.5/2.9 WNL/3.300. WNL/WNL (2)
04 04.3/<0.3 4.3/4.6 2.6/2.9 (5)
05 04.7/2.6 3.5/5.0 2.0/2.0 (5)
06 09.1/1.9 3.5/4.5 2.8/2.9 (24)
07 03.9/0.6 3.3/3.6 2.5/2.5 (7)
08 04.4/1.0 7.0/9.0 NA
09 08.6/6.8 4.5/3.5 2.6/2.9 (7)
10 05.1/3.4 5.0/4.8 3.5/3.2 (2)
11 15.9/0.70 5.2/5.5 4.0/4.0 (4)
12 05.6/NA 1.7/3.2 1.7/2.3 (2)
13 12.0/0.5 4.6/3.9 2.7/2.7 (12)
14 21.9/13.7 3.0/2.8 NA
15 12.6/3.80 5.0/4.0 NA
16 13.3/5.70 2.1/2.5 2.0/2.5 (2)
*Month: interval until follow-up echocardiography. CRP: C-reactive protein, LCA: left coronary artery, NA: not available, RCA: right coronary 
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kg) is strongly recommended in all children with persistent 
or recrudescent fever, proposals are lacking on how to treat 
the small group of refractory KD (3-4%) still remaining feb-
rile (up to one-third of IVIG-retreated patients).
12)13) There 
are different therapeutic approaches, including either a third 
dose of IVIG (2 g/kg) or pulse MP, although patients failing 
to respond to a second infusion of IVIG seem to be refracto-
ry to a third dose.
13-15) Some have identified predictors of IVIG 
nonresponsiveness.
16) But others have found no significant 
differences in characteristics between responders and non-
responders.
17) A study found that very early treatment of KD 
is likely to result in greater need for additional IVIG com-
pared to conventional treatment.
18) 
The use of corticosteroids in KD remains controversial. 
Reluctance to use corticosteroids for KD dates to Kato’s study 
in 1979, in the pre-IVIG era.
19) Others have reported the use of 
both intravenous MP and oral corticosteroids with good re-
sults, predominantly in patients with refractory disease.
20) 
Recent reports on the use of corticosteroids as “rescue thera-
py” in IVIG-refractory KD have not shown an association be-
tween corticosteroids and an increase in CAA.
7) However, tr-
eating refractory KD with corticosteroids should be under-
taken with caution. The possible transient adverse effects of 
corticosteroids include sinus bradycardia, hyperglycaemia, 
and hypertension.
21) In addition, even though fever initially 
resolved faster in patients receiving intravenous MP, there 
was a tendency for fever to recur later in MP-resistant patients, 
which delayed therapeutic decision-making, and ultimately 
the final resolution of fever.
22) Steroid treatment has also been 
reported to be a risk for development of CAA and rupture.
4) 
Infliximab is indicated for treating immune-modulated 
inflammatory disorders, including pediatric Crohn’s disease 
and juvenile idiopathic arthritis. 
23)24) In a recent study of inf-
liximab therapy in patients with KD who failed to respond 
to repeated IVIG infusions, patients demonstrated dramatic 
improvement with no adverse events.
8)10) 
It is thought to be beneficial in KD because TNF-α may be 
involved in the inflammatory process in acute KD. And recent-
ly, Hirono et al.
25) showed that serum concentrations of in-
terleukin-6 and soluble TNF receptor-1 dramatically decreas-
ed after infliximab treatment, and correlated with serum 
CRP concentrations and fevers. Hui-Yuen et al.
26) have shown 
that TNF-α is necessary for the development of CA lesions 
in an animal model of KD. 
Burns et al.
8) reported that complete response to inflix-
imab therapy with cessation of fever occurred in 14 of 16 
patients. Hirono et al.
25) reported that complete response to 
therapy with cessation of fever occurred in 8 of 11 patients. In 
our study, 13 of 16 patients (about 80%) had complete resp-
onse. CRP concentrations were elevated in all patients before 
infliximab infusion, and following the infusion they were low-
er in 14 patients in whom the concentrations were again de-
termined within 48 hours of treatment. 
In our series, 2 patients with fever and arthritis treated 
with infliximab achieved dramatic resolution of their arthri-
tis and fever within 12 hours of the infusion. Arthritis or ar-
thralgia can occur in patients in the acute or subacute stage 
of KD. A minority of patients suffer from severe intractable 
arthritis or arthralgia. As with our cases, in those patients in-
fliximab may prove useful.     
Based on current reports, the risk of development of CAA 
is highest in the group of patients who do not respond to a sin-
gle dose of IVIG. We saw rapidly progressive CA dilatation 
on frequent follow-up echocardiography in 4 refractory KD 
patients during MP pulse therapy. CA dilatation stopped, or 
the rate of progression at least slowed after infliximab treat-
ment. It may be that there is no significant additional progres-
sion of CA lesions after infliximab treatment, and that inflix-
imab treatment for refractory KD may prevent rapidly pro-
gressive CA dilatation. Fortunately, we did not have a fatal 
case. But there have been several fatal cases due to rapidly pro-
gressive CA dilatation with subsequent rupture.
4)
We recommend that for a patient with refractory KD, fre-
quent follow-up echocardiography is mandatory, and if a 
CAA progresses rapidly despite other therapies, including 
MP, early administration of infliximab should be considered. 
Serum concentrations of the proinflammatory cytokine 
TNF-α are elevated in CA disease and acute KD patients.
26)27) 
Therefore, it has been postulated that TNF-α blockade might 
be effective in the control of inflammation in patients with 
KD who fail to respond to IVIG. In our study, the cessation 
of fever and decrease in CRP levels following TNF-α blockade 
by infliximab treatment suggest that TNF-α is indeed an im-
portant mediator of inflammation in this vasculitis. The suc-
cess of TNF-α blockade in most patients in this study fur-
ther supports the central role of TNF-α in KD pathogenesis.
The pharmacodynamics, pharmocokinetics, and safety of 
infliximab in children have not yet been fully established. 
Similarly, the appropriate dose of infliximab for controlling 
inflammation in acute KD has not been determined. A dose 
of 5 mg/kg was used in the majority of patients in this series 
by extrapolation from data generated in pediatric patients 
with juvenile idiopathic arthritis and Crohn’s disease.
8)23)24) 
Other considerations regarding infliximab therapy for re-
fractory KD include cost and safety. The most common symp-
toms of immediate infusion reactions have been flushing 
and shortness of breath.
28) No infusion reactions were noted 
in our series. Complications of infliximab administration 
include reactivation of latent tuberculosis, histoplasmosis, 
increased risk of bacterial sepsis and lymphoma, develop-
ment of antinuclear antibodies, and heart failure.
8)29)30) There 
was only one mild complication in our series; acute hepatitis 
occurred during treatment and calculous cholecystitis occur-
red 4 months later, which subsided with supportive care. 338   Infliximab for Refractory Kawasaki Disease
Concentrations of antibody to infliximab were not meas-
ured in our study. Antibody formation should not be a prob-
lem in KD, because usually only 1 dose of infliximab is need-
ed. Because infliximab is administered only once for most 
patients with refractory KD, its administration may cause 
fewer complications in KD patients than in patients with Cro-
hn’s disease or juvenile idiopathic arthritis, where it is ad-
ministered repeatedly. 
Even though infliximab is efficacious but not without pos-
sible complications, we recommend it as second-line therapy 
for KD cases that are refractory to conventional therapy, un-
til the results of long-term studies are available. However, we 
cautiously propose that early administration of infliximab 
rather than a second IVIG treatment should be considered 
for patients with rapidly progressive CA dilatation.
The limitations of this study include its retrospective na-
ture, small number of patients, and the use of multiple dif-
ferent therapies following the first IVIG treatment failure. In 
addition, we did not determine proinflammatory cytokine 
concentrations before and after infliximab treatment. Differ-
ent IVIG preparations were used at each center. Concomitant 
anti-inflammatory therapies administered to several of these 
patients made it difficult to assess the effects of infliximab. 
In conclusion, our study suggests that infliximab can be 
useful not only in the treatment of refractory KD but also in 
the prevention of progression of CA lesions. There were no 
infusion reactions and complications attributed to inflix-
imab administration in 15 of 16 patients. Multicenter trials 
with a larger number of patients and long-term follow-up 
are necessary to assess the clinical efficacy and safety of inf-
liximab for refractory KD. 
REFERENCES
1)	Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new 
infantile acute febrile mucocutaneous lymph node syndrome (MLNS) 
prevailing in Japan. Pediatrics 1974;54:271-6.
2)	Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Ka-
wasaki disease: a 10- to 21-year follow-up study of 594 patients. Circula-
tion 1996;94:1379-85.
3)	Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawa-
saki syndrome with intravenous gamma globulin. N Engl J Med 1986; 
315:341-7.
4)	Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous 
infusion of gamma globulin as compared with four infusions in the tre-
atment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
5)	Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. In-
travenous gamma-globulin treatment and retreatment in Kawasaki 
disease. Pediatr Infect Dis J 1998;17:1144-8.
6)	Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Pra-
chuabmoh C, Kangkagate C. Immunoglobulin failure and retreat-
ment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8.
7)	Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of re-
fractory Kawasaki disease. J Rheumatol 2006;33:803-9.
8)	Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for re-
fractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
9)	Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treat-
ment, and long-term management of Kawasaki disease: a statement for 
health professionals from the Committee on Rheumatic Fever, Endo-
carditis and Kawasaki Disease, Council on Cardiovascular Disease in 
the Young, American Heart Association. Circulation 2004;110:2747-71.
10)	Weiss JE, Eberhard A, Chowdhury D, Gottlieb BS. Infliximab as a 
novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31: 
808-10.
11)	Research Committee on Kawasaki Disease. Report of subcommittee 
on standardization of diagnostic criteria and reporting of coronary 
artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health 
and Welfare; 1984. 
12)	Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma 
globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9.
13)	Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44.
14)	Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr In-
fect Dis J 2004;23:463-4.
15)	Nachiappan J, May M, Hawker RE, Hong P. Resistant Kawasaki dis-
ease. J Paediatr Child Health 2004;40:576-8.
16)	Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous 
immunoglobulin unresponsiveness in patients with Kawasaki dis-
ease. Circulation 2006;113:2606-12.
17)	Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-re-
sponsiveness to intravenous high-dose gamma-globulin therapy in 
patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.
18)	Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin 
treatment for Kawasaki disease: the nationwide surveys in Japan. J Pe-
diatr 2004;144:496-9. 
19)	Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment 
on coronary artery involvement. Pediatrics 1979;63:175-9.
20)	Wright DA, Newburger JW, Baker A, Sumdel RP. Treatment of im-
mune-globulin resistant Kawasaki disease with pulsed doses of corti-
costeroids. J Pediatr 1996;128:146-9.
21)	Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednis-
olone pulse therapy in refractory Kawasaki disease. Arch Dis Child 
2005;90:1096-7.
22)	Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashi-
ro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Ka-
wasaki disease. Arch Dis Child 2008;93:142-6.
23)	Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the 
treatment of children with refractory juvenile idiopathic arthritis: an 
open label study. Ann Rheum Dis 2003;62:245-7.
24)	Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMI-
CADE) therapy in the treatment of pediatric Crohn’s disease. Am J Ga-
stroenterol 2003;98:833-8.
25)	Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the 
cytokine-mediated inflammation but does not suppress cellular infil-
tration of the vessel wall in refractory Kawasaki disease. Pediatr Res 
2009;65:696-701.
26)	Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for in-
duction of coronary artery inflammation and aneurysm formation in 
an animal model of Kawasaki disease. J Immunol 2006;176:6294-301.
27)	Shin JU, Cho HK, Shin MS. Elevated tumor necrosis factor-alpha in 
stable angina pectoris. Korean Circ J 2000;30:861-6. 
28)	Crandall WV, Mackner LM. Infusion reactions to infliximab in chil-
dren and adolescents: frequency, outcome and a predictive model. 
Aliment Pharmacol Ther 2003;17:75-84.
29)	Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with inf-
liximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J 
Med 2001;345:1098-104.
30)	Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepato-
splenic T cell lymphoma associated with infliximab use in young pa-
tients treated for inflammatory bowel disease. J Pediatr Gastroenterol 
Nutr 2007;44:265-7. 